Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension
Shots:
- BI has launched Semintra (4mg/mL) in the EU for the treatment of systemic hypertension in cats
- Semintra has shown clinical efficacy in reducing proteinuria & blood pressure, which may help restore kidney balance while also promoting cat’s appetite, activity levels, & QoL
- Semintra (QD) is a telmisartan solution administered orally or on top of food using a mL-calibrated syringe. The US FDA has already approved Semintra it in 2013 & 2018 for feline proteinuria & hypertension, respectively
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
